NCT01840345

The Role of N-acetyl-l-cysteine (NAC) as an Adjuvant to Opioid Treatment in Patients With Chronic Neuropathic Pain

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 11 (actual)
• Sponsor: Virginia Commonwealth University · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This study will test whether treatment with N-acetyl-L-cysteine (NAC) is safe and decreases pain in patients with chronic neuropathic pain. The investigators hypothesize that NAC will be a useful adjunct to opioid treatment in chronic neuropathic pain.

Detailed description

This is an open-label study to evaluate the safety and efficacy of N-acetyl-L-cysteine in patients with Chronic neuropathic pain.

Conditions

• Neuropathic Pain

Interventions

Type	Name	Description
DRUG	N-acetyl-l-cysteine	1200 mg BID x 4 weeks

Timeline

• Start date: 2014-01-01
• Primary completion: 2017-03-01
• Completion: 2017-04-01
• First posted: 2013-04-25
• Last updated: 2018-05-14
• Results posted: 2018-05-14

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study